Page 1 |
Save page Remove page | Previous | 1 of 29 | Next |
|
small (250x250 max)
medium (500x500 max)
Large (1000x1000 max)
Extra Large
large ( > 500x500)
Full Resolution
All (PDF)
|
This page
All
|
FOLLICULAR DEVELOPMENT IN A SEVEN VERSUS FOUR DAY HORMONE-FREE
INTERVAL IN AN ORAL CONTRACEPTIVE CONTAINING 20 μG
ETHINYL ESTRADIOL AND 1 MG NORETHINDRONE ACETATE
by
Radhika D. Rible
________________________________________________________________________
A Thesis Presented to the
FACULTY OF THE GRADUATE SCHOOL OF THE
UNIVERSITY OF SOUTHERN CALIFORNIA
In partial fulfillment of the
requirements for the degree
MASTER OF SCIENCE
(CLINICAL AND BIOMEDICAL INVESTIGATIONS)
August 2008
Copyright 2008 Radhika D. Rible
Object Description
| Title | Follicular development in a seven versus four day hormone-free interval in an oral contraceptive containing 20 muG ethinyl estradiol and 1 mg norethindrone acetate |
| Author | Rible, Radhika D. |
| Author email | radhika@stanfordalumni.org; rrible@usc.edu |
| Degree | Master of Science |
| Document type | Thesis |
| Degree program | Clinical & Biomedical Investigations |
| School | Keck School of Medicine |
| Date defended/completed | 2008-07-01 |
| Date submitted | 2008 |
| Restricted until | Unrestricted |
| Date published | 2008-08-02 |
| Advisor (committee chair) | Mishell, Daniel R., Jr. |
| Advisor (committee member) |
Wilson, Melissa Stanczyk, Frank Z. |
| Abstract | Combined oral contraceptive (COC) formulations with 20 mcg ethinyl estradiol (EE) have a greater incidence of adverse symptoms than formulations with higher doses of estrogen, which can be managed by shortening the number of hormone-free days per COC cycle. This study evaluates differences in follicular development during a seven versus four day HFI in a COC regimen with 20 mcg EE and 1mg norethindrone acetate. Forty-one healthy women were randomized in an open-label fashion to this formulation in either a 24/4 or 21/7 day regimen for three cycles. Estradiol, progesterone, FSH, LH and inhibin B were measured daily from cycle 2, day 21 to cycle 3, day 3 and on day 8, of cycle 3. Follicular diameter and Hoogland score were calculated on cycle 2, days 21, 24, and 28 and cycle 3, days 3 and 7. Sixty-six percent of subjects in the 21/7 group and 70% of the subjects in the 24/4 group developed a follicle greater than 10mm diameter. Hormone levels, Hoogland scores, and bleeding patterns were not significantly different between the two groups. These findings may be due to characteristics of the subject population studied as well as the metabolic properties of norethindrone acetate. |
| Keyword | contraception; shortened hormone-free interval; follicular development |
| Language | English |
| Part of collection | University of Southern California dissertations and theses |
| Publisher (of the original version) | University of Southern California |
| Place of publication (of the original version) | Los Angeles, California |
| Publisher (of the digital version) | University of Southern California. Libraries |
| Provenance | Electronically uploaded by the author |
| Type | texts |
| Legacy record ID | usctheses-m1524 |
| Contributing entity | University of Southern California |
| Rights | Rible, Radhika D. |
| Repository name | Libraries, University of Southern California |
| Repository address | Los Angeles, California |
| Repository email | cisadmin@dots.usc.edu |
| Filename | etd-Rible-2180 |
| Archival file | uscthesesreloadpub_Volume40/etd-Rible-2180.pdf |
Description
| Title | Page 1 |
| Contributing entity | University of Southern California |
| Repository email | cisadmin@dots.usc.edu |
| Full text | FOLLICULAR DEVELOPMENT IN A SEVEN VERSUS FOUR DAY HORMONE-FREE INTERVAL IN AN ORAL CONTRACEPTIVE CONTAINING 20 μG ETHINYL ESTRADIOL AND 1 MG NORETHINDRONE ACETATE by Radhika D. Rible ________________________________________________________________________ A Thesis Presented to the FACULTY OF THE GRADUATE SCHOOL OF THE UNIVERSITY OF SOUTHERN CALIFORNIA In partial fulfillment of the requirements for the degree MASTER OF SCIENCE (CLINICAL AND BIOMEDICAL INVESTIGATIONS) August 2008 Copyright 2008 Radhika D. Rible |
